PHOSPHATE (P i ) plays a major role in growth, development, bone formation, and cellular metabolism. The kidney and small intestine are important sites that regulate body phosphate homeostasis. In both organs, sodium-coupled phosphate transport is the major form of P i absorption. The human and mouse intestinal sodium-dependent phosphate cotransporter (NaP i -IIb) cDNAs were cloned recently (9, 17, 34) , and the human NaP i -IIb cotransporter gene (SCLA34A2) was mapped to human chromosome 4p15. 1-15.3 (33, 34) .
Intestinal sodium-dependent phosphate absorption occurs predominantly through the NaP i cotransport system, while renal sodium-dependent phosphate absorption is mainly mediated by another closely related isoform, NaP i -IIa. In both tissues, P i absorption across the brush-border membrane through NaP i cotransporters is the rate-limiting step. Furthermore, P i absorption is tightly regulated to maintain body P i homeostasis. Many nutritional and endocrine factors regulate P i absorption in the intestine and kidney. For instance, a low-phosphate diet stimulates renal NaP i -IIa (5, 25, 28, 29) and intestinal NaP i -IIb cotransporter activity (16) . Also, vitamin D 3 and glucocorticoids affect renal and intestinal P i absorption (7, 27 ).
An important physiological regulator of renal P i absorption is epidermal growth factor (EGF), which acts through modulation of NaP i cotransporter activity (1, 2) . EGF is a 53-amino acid polypeptide, which is secreted predominantly by salivary glands, with lower levels excreted by kidney and many other tissues. EGF receptors are expressed along the intestinal tract (4) , and EFG has broad effects on cell division, DNA synthesis, tissue proliferation, cellular differentiation, and eletrocyte and nutrient absorption (24) . More specifically, EGF was shown to inhibit the activity of several intestinal brush-border membrane proteins including sucrase, maltase, and alkaline phosphatase (21) . Other studies showed that EGF inhibited renal P i uptake by modulating NaP i -IIa cotransporter protein and mRNA levels (1, 2) . Additionally, in some disease states, such as hyperphosphatemia induced by intestinal ischemia/ injury, serum P i levels are elevated (10, 19) , and EGF production and utilization are increased (30) . These observations suggest that EGF plays an important role in P i homeostasis by regulating renal and possibly intestinal P i absorption.
As reported in the current communication, we initially detected a significant decrease in intestinal NaP i -IIb mRNA abundance in EGF-treated rats and in human intestinal cells (Caco-2). These results suggested a possible role for EGF in transcriptional regulation of the NaP i -IIb gene. Therefore, to further understand the role of EGF in the regulation of intestinal P i homeostasis, we cloned the human NaP i -IIb gene and characterized in vitro regulation of the promoter by EGF.
MATERIALS AND METHODS
Animals. Suckling Sprague-Dawley rats (16 days old) received subcutaneous injections of human recombinant EGF (1 g/g body wt; Austral Biological, San Ramon, CA) or saline twice a day for 3 days. Fifteen hours after the last injection, rats were killed, and jejunal mucosa was harvested and used for mRNA purification. All animal work was approved by the University of Arizona Institutional Animal Care and Use Committee.
Cell culture. Human lung cells (A549) and human intestinal cells (Caco-2) were purchased from American Type Culture Collection (ATCC) and cultured according to ATCC guidelines. Cells were cultured at 37°C in a 95% air-5% CO 2 atmosphere and passaged every 72 h. Media and other reagents used for cell culture were purchased from Irvine Scientific (Irvine, CA).
RNA purification and Northern blot analyses. mRNA was isolated from A549 cells, Caco-2 cells, and rat jejunal mucosa with the FastTrack mRNA purification kit (Invitrogen, Carlsbad, CA). Part of the rat NaP i -IIb cDNA was amplified utilizing standard PCR conditions from rat jejunal cDNA, with highly conserved primers previously utilized for cloning of the human intestinal NaP i -IIb cDNA (34) . This rat cDNA fragment was subcloned and sequenced on both strands. Ten micrograms of mRNA were utilized for Northern blot analysis with rat or human NaP i -IIb cDNA-specific probes under high stringency washing conditions (6) . 1B15 (encoding cyclophilin) was utilized as a constitutive probe (6) . Blots were exposed to a phosphorimaging screen, and band intensities were determined with Quantity One software (FX Molecular Imager; Bio-Rad, Hercules, CA).
Semiquantitative RT-PCR analysis. mRNA was purified from Caco-2 cells treated with standard or EGF-containing medium (100 ng/ml). The primers used for detecting NaP i -IIb expression were the same as those previously described for cloning of the human intestinal NaP i -IIb cDNA (34) . The primers used for detecting ␤-actin and RT-PCR conditions were described previously (3) . Subsaturation levels of cDNA templates that were needed to produce a dose-dependent amount of PCR products were defined in initial experiments by testing a range of template concentrations. Subsequent PCR was carried out with subsaturation levels of RT reactions with identical parameters.
Isolation and characterization of genomic clones. A human genomic bacterial artificial chromosome (BAC) DNA library was screened by Research Genetics (Huntsville, AL) using a 32 P-labeled human intestinal NaP i -IIb 5Ј cDNA fragment (nt 175-350). Library screening resulted in three putativepositive clones, and one was selected for further analysis. Two strategies were undertaken to determine the human NaP i -IIb gene structure: 1) PCR amplification of BAC DNA with cDNA-specific primer pairs, and 2) direct sequencing of BAC DNA via primer walking. PCR products were then subcloned into pGEM-T vector (Promega, Madison, WI) and sequenced on both strands. For primer walking, BAC DNA was isolated from bacterial cultures by use of a standard plasmid DNA purification method. BAC DNA was treated with RNase A (Sigma, St. Louis, MO) and NotI restriction enzyme (Promega), and then extracted with phenol-chloroform, precipitated with EtOH, and resuspended in water. The BAC DNA was sequenced on both strands.
Primer extension. , and the RNA was degraded by adding 0.9 g DNase-free RNase A followed by incubation at 37°C for 30 min. The primer extension product was then EtOH precipitated, and the pellet was resuspended in 5 l loading dye/10 mM Tris-1 mM EDTA buffer, pH 8.0 (1:1). Samples were heated at 75°C for 10 min before loading on a sequencing gel. The gel was subsequently dried and exposed to Kodak Xomat Blue XB-1 film overnight at Ϫ70°C. A plasmid construct containing the human NaP i -IIb promoter region plus exons I and II (but missing intron 1) was used as a sequence template to indicate the size of primer extension products. This plasmid was constructed as follows. Initially, pZero-4.5 plasmid was built by inserting a SacIdigested BAC DNA fragment (ϳ4.5 kb) into pZero vector (Invitrogen). This 4.5-kb SacI fragment contained the 5Ј-flanking region, exon I, and part of intron 1 from the human NaP i -IIb gene. An Eco47III/XhoI-digested human NaP i -IIb cDNA fragment (726 bp) was then inserted into the Eco47III/ XhoI-digested pZero-4.5 vector (note that the Eco47III site is in exon I and the XhoI site is in the vector). Both plasmids were sequenced on both strands. The primer for the sequence reaction was the same one used for the primer extension reaction. The transcription initiation site was designated ϩ1; nucleotides upstream (i.e., 5Ј) were numbered negatively. Downstream nucleotides (i.e., 3Ј) were numbered positively.
Construction of reporter plasmids. Luciferase reporter plasmids used in this study were derived from pGL3 Basic (pGL3b; Promega). A Ϫ1,103/ϩ15 promoter reporter construct (pGL3-1,103) was made by subcloning a SacI/XmaIdigested pZero-4.5 fragment into pGL3b. A Ϫ181/ϩ15 promoter reporter construct (pGL3-181) was made by digesting pGL3-1,103 construct with SacI/ApaI and then blunting both ends with Klenow fragment of DNA polymerase I and ligating them together. A Ϫ380/ϩ15 promoter reporter construct (pGL3-380) was made by inserting a SacI/XmaI-digested PCR product, amplified with forward primer 5Ј-TATGAGCTCTTGAGCCTCACAG-GAG-3Ј at nt Ϫ361 to Ϫ380 (underlined nucleotides represent SacI site and overhanging bases) and reverse primer 5Ј-TATAGATCTCCGCAGGTGCTGGGCT-3Ј in intron 1 (underlined nucleotides indicate overhanging bases originally inserted for BglII subcloning not used for this construct), into pGL3b vector (note that the XmaI site is in exon I). A Ϫ2,783/ϩ15 promoter reporter construct (pGL3-2,783) was made by inserting a NotI/SacI-digested fragment (ϳ1.7 kb) into the pGL3-1,103 construct. This 1.7-kb fragment was originally amplified from BAC DNA with a high fidelity thermostable DNA polymerase using forward primer 5Ј-CGATCTTGGCTCAGTTGCAA-3Ј (nt-2783 to Ϫ2764) and reverse primer 5Ј-TTGTCTCCAATGTGCA-CACG-3Ј (nt Ϫ873 to Ϫ864) and cloned into the pTarget vector (Promega). In this strategy, SacI cut the human NaP i -IIb 5Ј-flanking region, and NotI cut the vectors. All constructs were sequenced to confirm the splice sites.
Transient transfection and functional promoter analysis. A549 and Caco-2 cells were cultured in 24-well plates. When cell density reached 60-70%, liposome-mediated transfection was performed as indicated. Promoter construct DNA (0.5 g), 30 ng pRL-CMV (Renilla luciferase reporter construct used as an internal standard; Promega), and 5 l Lipofectamine (GIBCO BRL, Grand Island, NY) were mixed with 200 l OptiMEM medium (GIBCO BRL) for 30 min at room temperature. The mixture was then added to the cells, and they were incubated for 5 h, followed by the addition of an equal volume of medium that contained 20% fetal bovine serum (FBS). The next day, the medium was removed and replaced with standard medium with 10% FBS. After 24 h, the cells were harvested for reporter gene assays. For EGF treatment, 100 ng/ml human recombinant EGF (Austral Biological) were added for 8 h before harvesting cells. To study the effect of actinomycin D on NaP i -IIb promoter activity, transiently transfected cells were pretreated with actinomycin D (5 g/ml) for 2 h before EGF treatment for 8 h in the presence of actinomycin D. Promoter reporter assays were performed using a dual luciferase assay kit according to the manufacturer's instructions (Promega).
Statistical analysis. The Student's t-test was used to compare values of the experimental data. P values of Ͻ0.05 were considered significant.
RESULTS

Effect of EGF treatment on NaP i -IIb mRNA levels in rat jejunum.
Northern blot analysis of mRNA isolated from rat jejunal mucosa is shown in Fig. 1 . Hybridization with a 757-bp rat intestinal NaP i -IIb cDNA probe clearly showed that NaP i -IIb mRNA abundance was decreased 50% by EGF administration (n ϭ 3; P ϭ 0.008). However, no change was observed for 1B15 mRNA abundance, which was used as an internal standard to normalize the NaP i -IIb signal. Furthermore, the rat NaP i -IIb cDNA fragment (GenBank accession no. AF247725) exhibited 93% nucleotide sequence homology with the mouse intestinal NaP i -IIb cDNA.
Effect of EGF treatment on NaP i -IIb mRNA levels in Caco-2 cells. Northern blot analysis of mRNA isolated from Caco-2 cells was performed by loading 10 g mRNA per gel lane. Hybridization with radiolabeled, 757-bp human intestinal NaP i -IIb cDNA-specific probes showed no signal from untreated or treated cells. However, the 1B15 hybridization signal was readily apparent (data not shown, n ϭ 3). These results suggested that the NaP i -IIb message was expressed below the Northern blot detection limits in Caco-2 cells under these culture conditions.
RT-PCR analysis of cells. Endogenous expression of human NaP i -IIb mRNA in human intestinal cells (Caco-2) and human lung cells (A549) was confirmed by RT-PCR using human intestinal NaP i -IIb primers (Fig. 2) . These results showed that an ϳ760-bp band was amplified from both cells. The PCR product was subcloned and sequenced, and it was 100% identical to the human NaP i -IIb cDNA. This indicated that these cells endogenously express the NaP i -IIb gene.
Effect of EGF treatment on NaP i -IIb mRNA levels in Caco-2 cells. The expression of human intestinal NaP i -IIb mRNA in Caco-2 cells after exposure to standard or EGF-containing medium was assessed by semiquantitative RT-PCR using human intestinal NaP i -IIb and ␤-actin primers (Fig. 3) . Data showed that human NaP i -IIb gene expression was significantly reduced by 40% in EGF-treated Caco-2 cells, Fig. 1 . The effect of epidermal growth factor (EGF) on rat intestinal sodium-phosphate cotransporter (NaP i -IIb) mRNA levels. A: 10 g mRNA isolated from rat jejunal mucosa was hybridized with rat NaP i -IIb cDNA and 1B15-specific probes. Blots were processed under high stringency conditions. Only two experimental results were shown. B: phosphorimage analysis of Northern blot data showed that EGF caused a 50% reduction of rat NaP i -IIb mRNA abundance. Results are means Ϯ SE. *P ϭ 0.008, n ϭ 3 groups, 6 rats/group. compared with untreated cells (n ϭ 3; P ϭ 0.02). This observation is in agreement with the in vivo observation that showed a ϳ50% decrease in NaP i -IIb mRNA abundance in EGF-treated rat intestine.
Genomic organization of the human NaP i -IIb gene. We focused our studies on one BAC clone. Direct sequencing of this BAC DNA identified intron 1 and intron 2. PCR amplification with different sets of primers identified introns 3-11 (Fig. 4) . The introns ranged in size from 91 to ϳ6,800 bp, whereas the exons ranged in size from 97 to 613 bp. The translation start site was located in exon II, and the translation stop site was located in exon XII. The human NaP i -IIb gene spans 24 kb and has 11 introns and 12 exons. DNA sequences at the intron/exon boundaries conformed to the general GT/AG rule for intron donor and acceptor splice sites. The intronic sequences determined on both strands have been deposited in GenBank with accession nos. AF234236-234245.
Mapping of the transcription initiation site of the human NaP i -IIb gene. The transcription initiation site was determined by primer extension with a reverse primer at cDNA nt 43-62. Figure 5A shows the primer extension results with mRNA isolated from both human lung cells (A549) and human intestinal cells (Caco-2). Two primer extension products were detected from both mRNA samples that aligned 106 bp and 119 bp upstream of the translation start site of human NaP i -IIb cDNA. This experiment was repeated three times, and identical results were obtained. and TRANSFAC promoter analysis software (32) . Search results showed that there was no TATA or CAAT box in the first 500 bp upstream of the transcription initiation site of the human NaP i -IIb gene. However, several other putative cis elements were identified, including transcriptional factors AP1, AP2, AP4, C/EBP, GATA1, and Sp1 binding sites. Furthermore, a putative glucocorticoid receptor binding site was identified further upstream (Ϫ1,082 bp). Promoter characterization of the human NaP i -IIb gene. To determine whether the 5Ј-flanking region of the human NaP i -IIb gene contained a functional promoter, four constructs (pGL3 Ϫ181/ϩ15, Ϫ380/ ϩ15, Ϫ1,103/ϩ15, and Ϫ2,783/ϩ15) were transfected into A549 and Caco-2 cells. Reporter gene assays were performed 48 h after transfection (Fig. 6) . The promoter assay data showed that all the promoter constructs were functional in both cell lines. Compared with the negative control transfections, these promoter constructs resulted in 10-to 17-fold stimulation of reporter gene activity (n ϭ 4-10; P Ͻ 0.002).
Effect of EGF on human NaP i -IIb gene promoter activity. To test the EGF effect on human NaP i -IIb gene promoter activity, A549 and Caco-2 cells were first transfected with promoter constructs and then treated with 100 ng/ml EGF before harvesting cells. Promoter activity was 40-50% decreased in Caco-2 cells after 8 h of EGF treatment (n ϭ 4-10; P Ͻ 0.02), but no change was seen in A549 cells (n ϭ 4-10) (Fig. 7) .
Effect of actinomycin D on human NaP i -IIb gene promoter activity induced by EGF.
To determine whether the EGF effect on human NaP i -IIb gene promoter activity is due to transcriptional regulation, Caco-2 cells were first transfected with promoter constructs and then treated with 5 g/ml actinomycin D for 2 h followed by treatment with 100 ng/ml EGF in the presence of actinomycin D. Results showed that the downregulation of NaP i -IIb promoter activity by EGF treatment in the Ϫ1,103 bp construct transfected cells was blocked by actinomycin D (n ϭ 4; P Ͻ 0.03) (Fig. 8) . Furthermore, there was no effect of either EGF or EGF/actinomycin D treatment in pGL3b or the Ϫ118 bp construct transfected cells (n ϭ 4).
DISCUSSION
EGF plays an important role in many physiological and pathophysiological processes, such as cell growth and recovery from injury. Additionally, it has been shown that the plasma P i level and EGF levels were increased with intestinal injury (10, 19, 30) . Thus EGF may play a role in regulation of P i homeostasis in response to intestinal injury. However, the precise relationship between EGF and intestinal P i absorption is not clear. In this study, we demonstrated that EGF treatment reduced intestinal NaP i -IIb mRNA abundance by 40-50% in rat and human intestinal cells (Caco-2). To decipher the molecular mechanism, we first cloned the human NaP i -IIb gene and promoter. We then characterized the gene promoter function and studied EGF regulation of promoter activity in transfected human lung and intestinal epithelial cells. Our data suggest for the first time that EGF reduces NaP i -IIb mRNA abundance via a gene transcriptionmediated mechanism.
Although EGF is clearly involved in regulating renal P i absorption, the role of EGF in modulating intestinal P i absorption is unknown. To understand the relationship between EGF and intestinal P i absorption, we cloned the complete human NaP i -IIb gene. Interestingly, the human NaP i -IIb gene showed structural differences when compared with the human NaP i -IIa gene (15) . The human NaP i -IIb gene is larger than the human NaP i -IIa gene (24 kb vs. 16 kb), although it has fewer exons and introns (12 exons/11 introns in NaP i -IIb vs. 13 exons/12 introns in NaP i -IIa). Also, in the human NaP i -IIb gene, intron 1 is the largest (ϳ6,800 bp), whereas in NaP i -IIa, intron 8 is the largest (ϳ5,000 bp). These differences may be the result of evolutionary divergence.
Furthermore, the human NaP i -IIb and NaP i -IIa genes showed differences in the 5Ј-flanking regions. Unlike the human NaP i -IIa gene promoter (15, 18) , the typical TATA box was absent in the proximal region of the human NaP i -IIb gene. However, in the TATA-less human NaP i -IIb gene promoter, several GATA1 binding sites are predicted. Previous studies showed that GATA transcription factors are involved in the regulation of cell type and tissue-specific gene expression (14, 20, 23, 31) . This finding is in agreement with the observation that this gene is expressed in only a few tissues [i.e., in human intestine, lung, and several glands (9, 34) ].
Because the NaP i -IIb gene was highly expressed in human intestine and lung, we chose a human intestinal cell line (Caco-2) and a human lung cell line (A549) for promoter characterization. RT-PCR studies demonstrated that NaP i -IIb mRNA was endogenously expressed in both Caco-2 and A549 cell lines, which suggested that they were appropriate in vitro models for promoter analyses. All four human NaP i -IIb gene promoter constructs (as described in MATERIALS AND METHODS) significantly stimulated reporter gene expression in both cell lines. This finding suggested that the basal promoter region of the gene is within the first 181 bp upstream of the transcription initiation site, since the shortest construct (Ϫ181/ϩ15) was active.
In vivo and in vitro studies showed that EGF treatment decreased intestinal NaP i -IIb mRNA abundance by ϳ50%, suggesting possible transcriptional regulation. In transient transfected Caco-2 cells, EGF also decreased NaP i -IIb gene promoter activity by ϳ40%. This promoter activity decrease could be abolished by actinomycin D, a transcriptional inhibitor. These data indicated that the effect of EGF on intestinal NaP i -IIb mRNA expression was due, at least in part, to reduced gene transcription. This reduction in promoter activity induced by EGF treatment was observed only in intestinal cells (Caco-2), but not in lung cells (A549), which suggested that the EGF effect on human NaP i -IIb gene expression was tissue specific.
Furthermore, the two larger promoter constructs (Ϫ1,103/ϩ15 and Ϫ2,783/ϩ15) were responsive to EGF treatment, but the two smaller ones (Ϫ181/ϩ15 and Ϫ380ϩ15) were not responsive. These data suggested that the putative EGF response element(s) was located between 380 and 1,103 bp upstream of the transcriptional unit. This observation also suggests that EGF regulation of this gene is not mediated by the basal transcriptional machinery, which is likely located within the first 200 bp upstream of transcription initiation site.
Several EGF responsive elements have been previously identified from the c-fos gene (11), the rat preprothyrotropin-release hormone gene (26) , the rat prolactin gene (8) , and the human gastrin gene (12, 13, 22) . These EGF responsive elements include a serum-response element and AP1 binding sequences in the c-fos gene and Sp1 binding sequences in the rat preprothyrotropin-release hormone gene and the human gastrin gene. We searched the human NaP i -IIb gene promoter region (Ϫ1,103 bp to Ϫ380 bp) for these known EGF response elements from these other genes, and we found two sequences (Ϫ792 bp GGGAAGG Ϫ786 bp and Ϫ479 bp GGGCGC Ϫ474 bp) that have high homology with the EGF response element of rat preprothyrotropin-release hormone gene. These sequences may be responsible for EGF regulation in the human NaP i -IIb gene, although further experiments will be required to make this determination.
In summary, we cloned the complete human NaP i -IIb gene from a human genomic BAC DNA library. This gene contains 12 exons and 11 introns. Approximately 2.8 kb of the 5Ј-flanking region of the human NaP i -IIb gene was sequenced and confirmed to be a functional promoter. EGF treatment decreased NaP i -IIb mRNA abundance in rat intestine and in human intestinal cells and also reduced the NaP i -IIb gene promoter activity in transfected human intestinal cells. Actinomycin D treatment blocked the promoter activity decrease induced by EGF treatment, confirming transcriptional regulation. These novel findings suggest that transcriptional mechanisms are involved in EGF regulation of intestinal NaP i -IIb cotransporter gene expression. Further studies will focus on identification of the EGF responsive element(s) and the transcription factors involved in EFG regulation of the human NaP i -IIb gene.
